BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting28-01-2022
28-01-2022
Accumulate BIOCON; target of Rs 422: Hem Securities
Hem Securities recommended hold rating on BIOCON with a target price of Rs 422 in its research report dated January 22, 2022.27-01-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting27-01-2022
Insulins access program for young expanded in Dec quarter: Biocon Biologics MD
Arun Chandavarkar, Managing Director, Biocon Biologics, in conversation with Business Today, spoke at length about Q3FY22 earnings and performance of the company's products.24-01-2022
R&D expenditure will rise in the coming quarters: Biocon Biologics MD
In a Q&A, Dr Arun Chandavarkar spoke on how its interchangeable insulin biosimilar has driven the business21-01-2022
Earnings Call for Q3FY22 of Biocon
Conference Call with Biocon Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.21-01-2022
Q3FY22 Quarterly Result Announced for Biocon Ltd.
Biotechnology firm Biocon declares Q3FY22 result: Biocon Q3FY22 Revenue at Rs 2,223 Cr, Up 18%; EBITDA at Rs 537 Cr, Up 25%; Biosimilars Up 28% at Rs 981 Cr; Research Services Up 10% at Rs 641 Cr Generics Up 7% at Rs 607 Cr Consolidated Revenue grew 18% to Rs 2,223 Crore from Rs 1,885 Crore in Q3FY21 Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 537 Crore (vs. Rs 428 Crore in Q3FY21) Core EBITDA* margins were at 33% Profit before Tax (PBT) was Rs 269 Crore (vs. Rs 236 Crore in Q3FY21) Net Profit was Rs 187 Crore (vs. Rs 169 Crore in Q3FY21) Commenting on the results, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said, “Biocon’s consolidated Q3FY22 revenues grew by 18% YoY to Rs 2,223 Crore, driven by a strong performance across all business segments. Biosimilars grew by 28% to Rs 981 Crore, Research Services was up 10% at Rs 641 Crore and Generics delivered a 7% growth at Rs 607 Crore. “EBITDA at Rs 537 Crore grew by 25%, which was impacted by mark- to- market loss attributed to Biocon Biologics’ equity investment in Adagio. Core EBITDA stood at Rs 715 Crore with a healthy margin of 33%. PBT for the quarter stood at Rs 269 Crore. Adjusted for Adagio related loss, PBT was higher at Rs 346 Crore, indicating a healthy operating profitability.” “Biocon Biologics achieved a key milestone with the commercialization of the world's first interchangeable biosimilar, our Insulin Glargine, in the U.S.. Approvals for several of our generics and biosimilars in global markets, and renewal of key long-term research service agreements at Syngene, position us for a strong close to this fiscal,” she added. Result PDF21-01-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation20-01-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on financial results for the quarter and nine months ended December 31, 2021.20-01-2022
BIOCON LTD. - 532523 - Financial Results For The Quarter Ended December 31, 2021
Financial Results for the quarter ended December 31, 202120-01-2022